Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021

Rhea-AI Summary

Myriad Genetics, Inc. (NASDAQ: MYGN) will release its financial results for the quarter ending March 31, 2021, on May 3, 2021, at 4:05 pm EDT. The company will not conduct a quarterly earnings call but will hold an Investor Day event on May 4, 2021, at 11:00 am EDT. This event will provide insights into the company's vision and future plans. Myriad is dedicated to advancing genetic testing and precision medicine to enhance patient care and reduce healthcare costs.

Positive

• Scheduled financial results release on May 3, 2021.
• Investor Day planned for May 4, 2021, offering strategic insights.

Negative

• No earnings call planned following quarterly results.

SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will release its financial results for the quarter ended March 31, 2021 at 4:05 pm EDT on May 3, 2021. The company will not be hosting a quarterly earnings call given it will be holding an Investor Day event the morning of May 4, 2021 at 11:00 am EDT. The link to the Investor Day event and registration will be under the investor relations section of our corporate website.

About Myriad Genetics
Myriad Genetics, Inc. is a leading genetic testing and precision medicine company dedicated to improving health and transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Media Contact:

Jared Maxwell (801) 505-5027 jmaxwell@myriad.com

Investor Contact:

Scott Gleason (801) 584-1143 sgleason@myriad.com

FAQ

When will Myriad Genetics release its Q1 2021 financial results?

Myriad Genetics will release its Q1 2021 financial results on May 3, 2021, at 4:05 pm EDT.

What is the date of the Investor Day for Myriad Genetics?

The Investor Day for Myriad Genetics is scheduled for May 4, 2021, at 11:00 am EDT.

Will there be an earnings call after the financial results are released?

No, Myriad Genetics will not hold a quarterly earnings call following the release of financial results.

What is Myriad Genetics known for?

Myriad Genetics is known for its leadership in genetic testing and precision medicine, focusing on improving health outcomes.